Sfoglia per Rivista
Molecular and clinical studies in hemochromatosis type 2 and 3
2000-01-01 De Gobbi M; Roetto A; Calì A; Daraio F; Barilaro MR; Totaro A; Gasparini P; Cazzola M; Camaschella C
Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology.
2014-01-01 De Rocco D; Bottega R; Cappelli E; Cavani S; Criscuolo M; Nicchia E; Corsolini F; Greco C; Borriello A; Svahn J; Pillon M; Mecucci C; Casazza G; Verzegnassi F; Cugno C; Locasciulli A; Farruggia P; Longoni D; Ramenghi U; Barberi W; Tucci F; Perrotta S; Grammatico P; Hanenberg H; Della Ragione F; Dufour C; Savoia A.
MODULATION OF THE IMMUNE MICROENVIROMENT IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMABBASED THERAPY: TUMOR CELL-EXTRINSIC EFFECTS OF DARATUMUMAB TREATMENT
2020-01-01 B. Castella, Mattia D’Agostino, C. Giannotta, S. Oliva, E. Genuardi, Milena Gilestro, M. Ruggeri, P. Corradini, B. Ziccheddu, F. Maura, S. Blasi, N. Bolli, A. Larocca, M. Boccadoro, M. Massaia.
Modulation of leukemic cell proliferation by tumor necrosis factor alpha.
1988-01-01 KERIM S ;PIACIBELLO W ;AGLIETTA M
MODULATION OF APOPTOSIS
2004-01-01 Saglio G; Morotti A; Cilloni D
Modulation by retinoic acid of the growth of bone marrow cell progenitors from patients with myelodysplastic syndrome.
1989-01-01 DE FRANCESCO A ;SANAVIO F ;STACCHINI A ;PIACIBELLO W ;QUAGLINO D ;AGLIETTA M
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement
2015-01-01 Pigazzi, Martina*; Manara, Elena; Buldini, Barbara; Beqiri, Valzerda; Bisio, Valeria; Tregnago, Claudia; Rondelli, Roberto; Masetti, Riccardo; Caterina Putti, Maria; Fagioli, Franca; Rizzari, Carmelo; Pession, Andrea; Locatelli, Franco; Basso, Giuseppe
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
2017-01-01 Simone, Ferrero; Martin, Dreyling
Minimal residual disease in acute myeloid leukemia detected by Wilms tumor gene 1 expression and multiparameter flow cytometry.
2014-01-01 4. FRAIRIA C., AYDIN S., RIERA L., ALIBERTI S., ALLIONE B, AUDISIO E., D'ARDIA S., DEMURTAS A., FRANCIA DI CELLE P., NICOLINO B., PECORARO C., STACCHINI A., MARMONT M., VITOLO U
MINIMAL RESIDUAL DISEASE (MRD) DETECTION BY NEXT GENERATION SEQUENCING AND REAL TIME QUANTITATIVE–PCR: A METHODICAL COMPARISON IN ALL, MCL AND MM
2013-01-01 Ladetto M.; Bruggeman M; Monitillo L.
Il Mieloma multiplo.
1991-01-01 Boccadoro M; Battaglio S; Dianzani U; Frieri R; Gallone G; Massaia M; Omedè P; Palumbo A; Pileri A
Microsatellite analysis in childhood acute lymphoblastic leukemia
1998-01-01 Reato G; Basso G; Putti MC; Cignetti A; Guarini A; Foa R
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)
2008-01-01 M. Coscia; S. Peola; G. Matta; F. Pantaleoni; M. Foglietta; C. Vitale; D. Angelini; S. Chiaretti; C. Riganti; A. Guarini; D. Drandi; M. Ladetto; A. Bosia; R. Foà; L. Battistini; M. Boccadoro; J.J. Fournie; M. Massaia
Mesenchymal stem cells isolated from amniotic fluid differentiate in neuronal cells
2008-01-01 Mareschi K; Rustichelli D; Ferrero I; Comunanza V; Fazio R; Saglio F; Martinoglio B; Medico E; Carbone E; Benedetto C; Fagioli F
Mesenchymal stem cells isolated from amniotic fluid differentiate in neuronal cells
2007-01-01 Rustichelli D; Mareschi K; Ferrero I; Manetta T; De Fazio R; Anselmino A; Morterra G; Gunetti M; Comunanza V; Carbone E; Fagioli F
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSUS HIGHDOSEMELPHALAN AND AUTOLOGOUS TRANSPLANTATION (MEL200)IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: APHASE III STUDY
2011-01-01 A Palumbo; F Cavallo; B Lupo; A Nagler; V Redoglia; M Cavalli; A Carella; A Cafro; F Patriarca; A Siniscalchi; F Rossini; C Crippa; P Corradini; M Cavo; S Grammatico; A Stanevsky; D Ben Yehuda; F Di Raimondo; T Caravita Di Toritto; M Boccadoro
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSO MELPHALAN (200 MG/M2) E TRAPIANTO AUTOLOGO (MEL200) IN PAZIENTI CON NUOVA DIAGNOSI DI MIELOMA MULTIPLO (MM): UNO STUDIO DI FASE III.
2011-01-01 Cavallo F; Lupo B; Di Raimondo F; Ben Yehuda D; Corradini P; Patriarca F; Cavo M; Carella AM; Omedè P; Stanevsky S;Siniscalchi A; Cavalli M; Marcatti M; Petrò D; Crippa C; Levi A; Caravita Di Toritto T; Nagler A; Boccadoro M; Palumbo A
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
2010-01-01 Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA.
Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway.
2014-01-01 P. Sciancalepore; B. Castella; J. Kopecka; I. Campia; G. Gelsomino; M. Foglietta; D. Ghigo; M. Boccadoro; C. Riganti; M. Massaia.
Marriage and parenthood among subjects cured of childhood cancer: a report from the Italian AIEOP Off-Therapy Registry
2011-01-01 Pivetta E; Maule MM; Pisani P; Zugna D; Haupt R; Jankovic M; Arico' M; Casale F; Clerico A; Cordero di Montezemolo L; Kiren V; Locatelli F; Palumbo G; Pession A; Pillon M; Santoro N; Terenziani M; Valsecchi MG; Dama E; Magnani C; Merletti F; Pastore G.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Molecular and clinical studies in hemochromatosis type 2 and 3 | 2000 | De Gobbi M; Roetto A; Calì A; Daraio F; Barilaro MR; Totaro A; Gasparini P; Cazzola M; Camaschella C | |
Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology. | 2014 | De Rocco D; Bottega R; Cappelli E; Cavani S; Criscuolo M; Nicchia E; Corsolini F; Greco C; Borriello A; Svahn J; Pillon M; Mecucci C; Casazza G; Verzegnassi F; Cugno C; Locasciulli A; Farruggia P; Longoni D; Ramenghi U; Barberi W; Tucci F; Perrotta S; Grammatico P; Hanenberg H; Della Ragione F; Dufour C; Savoia A. | |
MODULATION OF THE IMMUNE MICROENVIROMENT IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMABBASED THERAPY: TUMOR CELL-EXTRINSIC EFFECTS OF DARATUMUMAB TREATMENT | 2020 | B. Castella, Mattia D’Agostino, C. Giannotta, S. Oliva, E. Genuardi, Milena Gilestro, M. Ruggeri, P. Corradini, B. Ziccheddu, F. Maura, S. Blasi, N. Bolli, A. Larocca, M. Boccadoro, M. Massaia. | |
Modulation of leukemic cell proliferation by tumor necrosis factor alpha. | 1988 | KERIM S ;PIACIBELLO W ;AGLIETTA M | |
MODULATION OF APOPTOSIS | 2004 | Saglio G; Morotti A; Cilloni D | |
Modulation by retinoic acid of the growth of bone marrow cell progenitors from patients with myelodysplastic syndrome. | 1989 | DE FRANCESCO A ;SANAVIO F ;STACCHINI A ;PIACIBELLO W ;QUAGLINO D ;AGLIETTA M | |
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement | 2015 | Pigazzi, Martina*; Manara, Elena; Buldini, Barbara; Beqiri, Valzerda; Bisio, Valeria; Tregnago, Claudia; Rondelli, Roberto; Masetti, Riccardo; Caterina Putti, Maria; Fagioli, Franca; Rizzari, Carmelo; Pession, Andrea; Locatelli, Franco; Basso, Giuseppe | |
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? | 2017 | Simone, Ferrero; Martin, Dreyling | |
Minimal residual disease in acute myeloid leukemia detected by Wilms tumor gene 1 expression and multiparameter flow cytometry. | 2014 | 4. FRAIRIA C., AYDIN S., RIERA L., ALIBERTI S., ALLIONE B, AUDISIO E., D'ARDIA S., DEMURTAS A., FRANCIA DI CELLE P., NICOLINO B., PECORARO C., STACCHINI A., MARMONT M., VITOLO U | |
MINIMAL RESIDUAL DISEASE (MRD) DETECTION BY NEXT GENERATION SEQUENCING AND REAL TIME QUANTITATIVE–PCR: A METHODICAL COMPARISON IN ALL, MCL AND MM | 2013 | Ladetto M.; Bruggeman M; Monitillo L. | |
Il Mieloma multiplo. | 1991 | Boccadoro M; Battaglio S; Dianzani U; Frieri R; Gallone G; Massaia M; Omedè P; Palumbo A; Pileri A | |
Microsatellite analysis in childhood acute lymphoblastic leukemia | 1998 | Reato G; Basso G; Putti MC; Cignetti A; Guarini A; Foa R | |
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) | 2008 | M. Coscia; S. Peola; G. Matta; F. Pantaleoni; M. Foglietta; C. Vitale; D. Angelini; S. Chiaretti; C. Riganti; A. Guarini; D. Drandi; M. Ladetto; A. Bosia; R. Foà; L. Battistini; M. Boccadoro; J.J. Fournie; M. Massaia | |
Mesenchymal stem cells isolated from amniotic fluid differentiate in neuronal cells | 2008 | Mareschi K; Rustichelli D; Ferrero I; Comunanza V; Fazio R; Saglio F; Martinoglio B; Medico E; Carbone E; Benedetto C; Fagioli F | |
Mesenchymal stem cells isolated from amniotic fluid differentiate in neuronal cells | 2007 | Rustichelli D; Mareschi K; Ferrero I; Manetta T; De Fazio R; Anselmino A; Morterra G; Gunetti M; Comunanza V; Carbone E; Fagioli F | |
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSUS HIGHDOSEMELPHALAN AND AUTOLOGOUS TRANSPLANTATION (MEL200)IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: APHASE III STUDY | 2011 | A Palumbo; F Cavallo; B Lupo; A Nagler; V Redoglia; M Cavalli; A Carella; A Cafro; F Patriarca; A Siniscalchi; F Rossini; C Crippa; P Corradini; M Cavo; S Grammatico; A Stanevsky; D Ben Yehuda; F Di Raimondo; T Caravita Di Toritto; M Boccadoro | |
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSO MELPHALAN (200 MG/M2) E TRAPIANTO AUTOLOGO (MEL200) IN PAZIENTI CON NUOVA DIAGNOSI DI MIELOMA MULTIPLO (MM): UNO STUDIO DI FASE III. | 2011 | Cavallo F; Lupo B; Di Raimondo F; Ben Yehuda D; Corradini P; Patriarca F; Cavo M; Carella AM; Omedè P; Stanevsky S;Siniscalchi A; Cavalli M; Marcatti M; Petrò D; Crippa C; Levi A; Caravita Di Toritto T; Nagler A; Boccadoro M; Palumbo A | |
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial | 2010 | Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA. | |
Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway. | 2014 | P. Sciancalepore; B. Castella; J. Kopecka; I. Campia; G. Gelsomino; M. Foglietta; D. Ghigo; M. Boccadoro; C. Riganti; M. Massaia. | |
Marriage and parenthood among subjects cured of childhood cancer: a report from the Italian AIEOP Off-Therapy Registry | 2011 | Pivetta E; Maule MM; Pisani P; Zugna D; Haupt R; Jankovic M; Arico' M; Casale F; Clerico A; Cordero di Montezemolo L; Kiren V; Locatelli F; Palumbo G; Pession A; Pillon M; Santoro N; Terenziani M; Valsecchi MG; Dama E; Magnani C; Merletti F; Pastore G. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile